- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03356795
Intervención de CAR-T Contra el Cáncer de Cuello Uterino
Ensayo multicéntrico de células T modificadas con receptor de antígeno quimérico (células CAR-T) en el tratamiento del cáncer de cuello uterino
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Cervical cancer is a cancer arising from the cervix. Human papillomavirus (HPV) infection causes more than 90% of cases. Other risk factors include smoking, a weak immune system, birth control pills, starting sex at a young age, and having many sexual partners, but these are less important. Worldwide, cervical cancer is both the fourth-most common cause of cancer and the fourth-most common cause of death from cancer in women. The treatment of cervical cancer consists of surgical intervention, radiation, chemotherapy and immunotherapy.
In this study, the participant's T-cells will be collected and modified. Then the modified T cells, called chimeric antigen receptor modified-T cells (CAR T) which can recognize specific molecules that are expressed on the surface of cervical cancer cells, are given back to the participant by intravenous infusion.
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Guangdong
-
Shenzhen, Guangdong, Porcelana, 518000
- Shenzhen Geno-immune Medical Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Patients with stage III, IV or relapsed cervical cancer confirmed by histology and biopsy.
-
Age: ≥ 18 years and ≤ 70 years.
-
4 weeks at least since last chemotherapy or radiotherapy and 2 weeks at least since last systemic steroid hormone and other immunosuppressive therapy.
-
Side Effects of Chemotherapy have subsided.
-
GD2, PSMA, Muc1, Mesothelin or other markers is expressed high (above 2+) in malignancy tissues by immuno-histochemical or flow cytometry.
-
Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
-
Expected survival ≥ 12 weeks.
-
Initial hematopoietic reconstitution with
- neutrophils (ANC) ≥ 1×10^6/L;
- platelet (PLT) ≥ 1×10^8/L.
-
Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with
- serum creatinine ≤ 2×ULN;
- serum bilirubin ≤ 3×ULN;
- AST/ALT ≤ 2.5×ULN.
-
Oxygen saturation ≥ 90%.
-
Written, informed consent obtained prior to any study-specific procedures.
Exclusion Criteria:
-
Airway obstruction caused by tumor.
-
History of epilepsy or other central nervous system diseases.
-
Patients who require systemic corticosteroid or other immunosuppressive therapy.
-
History of prolonged or serious heart disease during QT.
-
history of serious cyclophosphamide toxicity.
-
Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study.
-
Inadequate liver and renal function with
- serum creatinine > 1.5 mg/dl;
- serum (total) bilirubin > 2.0 mg/dl;
- AST & ALT > 3 x ULN.
-
Pregnant or lactating females.
-
Serious active infection during screening.
-
Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection.
-
Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Cervical cancer-specific CAR-T cells
Peripheral blood mononuclear cells (PBMCs) of patients who have GD2, PSMA, Muc1 or Mesothelin positive cervical cancer will be obtained through apheresis, and T cells will be activated and modified to cervical cancer-specific CAR-T cells. |
1 infusion, for 1x10^6~1x10^7 cells/kg via IV |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety of CART cells in patients using CTCAE version 4.0 standard to evaluate the level of adverse events
Periodo de tiempo: 3 months
|
Physiological parameter (measuring cytokine response) |
3 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Persistence and proliferation of CART cells in patients
Periodo de tiempo: 3 months
|
The expansion and functional persistence of CART cells in the peripheral blood of patients will be measured by qPCR on Day 7, 14, 21, 28, 60 and 90 after infusion. |
3 months
|
|
Anti-tumor effects
Periodo de tiempo: 1 year
|
Objective response, such as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. |
1 year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Lung-Ji Chang, PhD, Shenzhen Geno-Immune Medical Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades uterinas
- Enfermedades Genitales Femeninas
- Neoplasias Genitales Femeninas
- Enfermedades del cuello uterino
- Neoplasias Uterinas
- Neoplasias del cuello uterino
- Enfermedad renal quística medular 1
Otros números de identificación del estudio
- GIMI-IRB-17017
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .